Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023. | Oncologist | 2024 | 38048064 | PubTator, text mining | PubMed |
| Global Transcriptome Analysis Reveals Distinct Phases of the Endothelial Response to TNF. | J Immunol | 2024 | 38019121 | PubTator, text mining | PubMed |
| LINC00887 regulates malignant progression and T-cell chemotaxis in clear cell renal cell carcinoma by activating CD70 via recruitment of SPI1. | Gene | 2024 | 37858743 | PubTator, text mining | PubMed |
| Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy. | Haematologica | 2024 | 37706315 | PubTator, text mining | PubMed |
| PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases. | J Clin Pathol | 2024 | 37696593 | PubTator, text mining | PubMed |
| Dominance and improved survivability of human γδT17 cell subset aggravates the immunopathogenesis of pemphigus vulgaris. | Immunol Res | 2024 | 37620509 | PubTator, text mining | PubMed |
| Integrated bulk and single-cell transcriptome data identify clinically relevant cell populations in clear cell renal cell carcinoma. | Genes Dis | 2024 | 37588222 | PubTator, text mining | PubMed |
| Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin. | Genes Dis | 2024 | 37588187 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Expression and Pathway for CD27 in Esophageal Cancer. | Mol Biotechnol | 2024 | 37584826 | PubTator, text mining | PubMed |
| Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing. | Front Pharmacol | 2023 | 38293666 | PubTator, text mining | PubMed |
| Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity. | Front Immunol | 2023 | 38283365 | PubTator, text mining | PubMed |
| Immunotherapeutic approaches for systemic lupus erythematosus: early overview and future potential. | Med Rev (2021) | 2023 | 38282801 | PubTator, text mining | PubMed |
| Unresectable leiomyosarcoma of the inferior vena cava with right atrium tumor thrombus: when to deem this tumor inoperable? A case report and literature review. | Front Oncol | 2023 | 38282675 | PubTator, text mining | PubMed |
| Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy. | Front Immunol | 2023 | 38274827 | PubTator, text mining | PubMed |
| Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study. | Front Immunol | 2023 | 38268915 | PubTator, text mining | PubMed |
| Establishment of a pathomic-based machine learning model to predict CD276 (B7-H3) expression in colon cancer. | Front Oncol | 2023 | 38260829 | PubTator, text mining | PubMed |
| Treg in inborn errors of immunity: gaps, knowns and future perspectives. | Front Immunol | 2023 | 38259469 | PubTator, text mining | PubMed |
| CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype. | J Immunother Cancer | 2023 | 38251688 | PubTator, text mining | PubMed |
| A comprehensive battery of flow cytometric immunoassays for the in vitro testing of chemical effects in human blood cells. | Front Immunol | 2023 | 38229911 | PubTator, text mining | PubMed |
| The Plastic Interplay between Lung Regeneration Phenomena and Fibrotic Evolution: Current Challenges and Novel Therapeutic Perspectives. | Int J Mol Sci | 2023 | 38203718 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=18